{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:09:06Z","timestamp":1783116546017,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,29]],"date-time":"2009-11-29T00:00:00Z","timestamp":1259452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s11906-009-0076-8","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T06:04:06Z","timestamp":1259388246000},"page":"450-455","source":"Crossref","is-referenced-by-count":19,"title":["Aldosterone and cardiovascular risk"],"prefix":"10.1007","volume":"11","author":[{"given":"Bruno","family":"Vogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,29]]},"reference":[{"key":"76_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","volume":"186","author":"J.M. Connell","year":"2005","unstructured":"Connell JM, Davies E: The new biology of aldosterone. J Endocrinol 2005, 186:1\u201320.","journal-title":"J Endocrinol"},{"key":"76_CR2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.physiol.64.082101.143243","volume":"64","author":"B.C. Rossier","year":"2002","unstructured":"Rossier BC, Pradervand S, Schild L, et al.: Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annu Rev Physiol 2002, 64:877\u2013897.","journal-title":"Annu Rev Physiol"},{"key":"76_CR3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1440-1681.2003.03867.x","volume":"30","author":"E. Davies","year":"2003","unstructured":"Davies E, Mackenzie SM: Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 2003, 30:437\u2013445.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"76_CR4","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1210\/en.2004-0295","volume":"145","author":"E.P. Gomez-Sanchez","year":"2004","unstructured":"Gomez-Sanchez EP, Ahmad N, Romero DG, et al.: Origin of aldosterone in the rat heart. Endocrinology 2004, 145:4796\u20134802.","journal-title":"Endocrinology"},{"key":"76_CR5","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","volume":"273","author":"J.S. Silvestre","year":"1998","unstructured":"Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883\u20134891.","journal-title":"J Biol Chem"},{"key":"76_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","volume":"29","author":"J.M. Connell","year":"2008","unstructured":"Connell JM, Mackenzie SM, Freel EM, et al.: A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008, 29:133\u2013154.","journal-title":"Endocr Rev"},{"key":"76_CR7","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R. Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"76_CR8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","volume":"12","author":"R. Rocha","year":"2001","unstructured":"Rocha R, Stier CT Jr: Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001, 12:308\u2013314.","journal-title":"Trends Endocrinol Metab"},{"key":"76_CR9","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R. Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802\u2013H1810.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"76_CR10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.ASN.0000017902.77985.84","volume":"13","author":"Q. Wang","year":"2002","unstructured":"Wang Q, Hummler E, Nussberger J, et al.: Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes. J Am Soc Nephrol 2002, 13:1509\u20131516.","journal-title":"J Am Soc Nephrol"},{"key":"76_CR11","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"K.T. Weber","year":"1991","unstructured":"Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849\u20131865.","journal-title":"Circulation"},{"key":"76_CR12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"C.G. Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563\u2013575.","journal-title":"J Mol Cell Cardiol"},{"key":"76_CR13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"E.R. Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, et al.: Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791\u20131800.","journal-title":"Kidney Int"},{"key":"76_CR14","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/ndt\/gfm321","volume":"22","author":"M. Burnier","year":"2007","unstructured":"Burnier M, Phan O, Wang Q: High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol Dial Transplant 2007, 22:2426\u20132429.","journal-title":"Nephrol Dial Transplant"},{"key":"76_CR15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","volume":"75","author":"W.B. Lea","year":"2009","unstructured":"Lea WB, Kwak ES, Luther JM, et al.: Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009, 75:936\u2013944.","journal-title":"Kidney Int"},{"key":"76_CR16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"R.S. Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33\u201341.","journal-title":"N Engl J Med"},{"key":"76_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjhyper.2004.12.005","volume":"18","author":"S. Kathiresan","year":"2005","unstructured":"Kathiresan S, Larson MG, Benjamin EJ, et al.: Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005, 18:657\u2013665.","journal-title":"Am J Hypertens"},{"key":"76_CR18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.HYP.0000154364.00763.d5","volume":"45","author":"C.E. Grim","year":"2005","unstructured":"Grim CE, Cowley AW Jr, Hamet P, et al.: Hyperaldosteronism and hypertension: ethnic differences. Hypertension 2005, 45:766\u2013772.","journal-title":"Hypertension"},{"key":"76_CR19","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K. Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, et al.: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730\u20131736.","journal-title":"Circulation"},{"key":"76_CR20","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","volume":"114","author":"F. Beygui","year":"2006","unstructured":"Beygui F, Collet JP, Benoliel JJ, et al.: High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006, 114:2604\u20132610.","journal-title":"Circulation"},{"key":"76_CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"76_CR22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"76_CR23","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","volume":"69","author":"C.S. Fox","year":"2006","unstructured":"Fox CS, Larson MG, Hwang SJ, et al.: Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006, 69:2064\u20132069.","journal-title":"Kidney Int"},{"key":"76_CR24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","volume":"19","author":"G.P. Rossi","year":"2008","unstructured":"Rossi GP, Sechi LA, Giacchetti G, et al.: Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008, 19:88\u201390.","journal-title":"Trends Endocrinol Metab"},{"key":"76_CR25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P. Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243\u20131248.","journal-title":"J Am Coll Cardiol"},{"key":"76_CR26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C. Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, et al.: Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008, 168:80\u201385.","journal-title":"Arch Intern Med"},{"key":"76_CR27","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"L.A. Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, et al.: Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006, 295:2638\u20132645.","journal-title":"JAMA"},{"key":"76_CR28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","volume":"94","author":"M. Reincke","year":"2009","unstructured":"Reincke M, Rump LC, Quinkler M, et al.: Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metabol 2009, 94:869\u2013875.","journal-title":"J Clin Endocrinol Metabol"},{"key":"76_CR29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","volume":"150","author":"J.R. Sowers","year":"2009","unstructured":"Sowers JR, Whaley-Connell A, Epstein M: Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776\u2013783.","journal-title":"Ann Intern Med"},{"key":"76_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1507\/endocrj.51.243","volume":"51","author":"R. Yamashita","year":"2004","unstructured":"Yamashita R, Kikuchi T, Mori Y, et al.: Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 2004, 51:243\u2013251.","journal-title":"Endocr J"},{"key":"76_CR31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0960-0760(03)00072-4","volume":"84","author":"C. Calle","year":"2003","unstructured":"Calle C, Campion J, Garcia-Arencibia M, et al.: Transcriptional inhibition of the human insulin receptor gene by aldosterone. J Steroid Biochem Mol Biol 2003, 84:543\u2013553.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"76_CR32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G. Giacchetti","year":"2007","unstructured":"Giacchetti G, Ronconi V, Turchi F, et al.: Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007, 25:177\u2013186.","journal-title":"J Hypertens"},{"key":"76_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.33549\/physiolres.930000.49.241","volume":"49","author":"J. Widimsky Jr","year":"2000","unstructured":"Widimsky J Jr, Sindelka G, Haas T, et al.: Impaired insulin action in primary hyperaldosteronism. Physiol Res 2000, 49:241\u2013244.","journal-title":"Physiol Res"},{"key":"76_CR34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.33549\/physiolres.930298","volume":"52","author":"B. Strauch","year":"2003","unstructured":"Strauch B, Widimsky J, Sindelka G, et al.: Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 2003, 52:503\u2013506.","journal-title":"Physiol Res"},{"key":"76_CR35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.33549\/physiolres.930123","volume":"50","author":"J. Widimsky Jr","year":"2001","unstructured":"Widimsky J Jr, Strauch B, Sindelka G, et al.: Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res 2001, 50:603\u2013607.","journal-title":"Physiol Res"},{"key":"76_CR36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.ijo.0801483","volume":"25","author":"G. Andronico","year":"2001","unstructured":"Andronico G, Cottone S, Mangano MT, et al.: Insulin, reninaldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001, 25:239\u2013242.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"76_CR37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.25.1.30","volume":"25","author":"T.L. Goodfriend","year":"1995","unstructured":"Goodfriend TL, Egan B, Stepniakowski K, et al.: Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995, 25:30\u201336.","journal-title":"Hypertension"},{"key":"76_CR38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","volume":"49","author":"S. Kidambi","year":"2007","unstructured":"Kidambi S, Kotchen JM, Grim CE, et al.: Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007, 49:704\u2013711.","journal-title":"Hypertension"},{"key":"76_CR39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F. Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, et al.: Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metabol 2006, 91:454\u2013459.","journal-title":"J Clin Endocrinol Metabol"},{"key":"76_CR40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/07435809809032689","volume":"24","author":"T.L. Goodfriend","year":"1998","unstructured":"Goodfriend TL, Egan BM, Kelley DE: Aldosterone in obesity. Endocrin Res 1998, 24:789\u2013796.","journal-title":"Endocrin Res"},{"key":"76_CR41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/plef.2002.0414","volume":"67","author":"T.L. Goodfriend","year":"2002","unstructured":"Goodfriend TL, Ball DL, Gardner HW: An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids 2002, 67:163\u2013167.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"76_CR42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.semnephrol.2007.07.009","volume":"27","author":"B. Vogt","year":"2007","unstructured":"Vogt B, Bochud M, Burnier M: The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol 2007, 27:529\u2013537.","journal-title":"Semin Nephrol"},{"key":"76_CR43","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ajh\/7.10.886","volume":"7","author":"B.M. Egan","year":"1994","unstructured":"Egan BM, Stepniakowski K, Goodfriend TL: Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertension 1994, 7:886\u2013893.","journal-title":"Am J Hypertension"},{"key":"76_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M. Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P, et al.: Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006, 48:239\u2013245.","journal-title":"Hypertension"},{"key":"76_CR45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjhyper.2004.08.008","volume":"18","author":"B.M. Egan","year":"2005","unstructured":"Egan BM, Papademetriou V, Wofford M, et al.: Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertension 2005, 18:3\u201312.","journal-title":"Am J Hypertension"},{"key":"76_CR46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/HYPERTENSIONAHA.108.122002","volume":"53","author":"J. Matrozova","year":"2009","unstructured":"Matrozova J, Steichen O, Amar L, et al.: Fasting glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009, 53:605\u2013610.","journal-title":"Hypertension"},{"key":"76_CR47","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJM198104163041602","volume":"304","author":"M.L. Tuck","year":"1981","unstructured":"Tuck ML, Sowers J, Dornfeld L, et al.: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304:930\u2013933.","journal-title":"N Engl J Med"},{"key":"76_CR48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.numecd.2008.06.001","volume":"19","author":"C. Dall\u2019Asta","year":"2009","unstructured":"Dall\u2019Asta C, Vedani P, Manunta P, et al.: Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009, 19:110\u2013114.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"76_CR49","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"P.J. Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109\u20132122.","journal-title":"N Engl J Med"},{"key":"76_CR50","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","volume":"154","author":"M.J. Forrest","year":"2008","unstructured":"Forrest MJ, Bloomfield D, Briscoe RJ, et al.: Torcetrapibinduced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008, 154:1465\u20131473.","journal-title":"Br J Pharmacol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-009-0076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-009-0076-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-009-0076-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T13:34:30Z","timestamp":1739453670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-009-0076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,29]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s11906-009-0076-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,29]]}}}